Ovarian Cancer Research Alliance Community Partner

RSS News

  • FDA Grants Fast Track Status to Celsion’s GEN-1 for Advanced Cancer February 25, 2021
    Celsion‘s immunotherapy candidate, GEN-1, has received fast track designation from the U.S. Food and Drug Administration (FDA) for advanced ovarian cancer. This designation helps speed the approval of potential medicines that address unmet medical needs in serious or life-threatening conditions. It grants greater access to FDA input throughout the regulatory process and makes GEN-1 eligible […]
  • She ROCKS Raises $100K to Support Early Work Into Stem Cell Therapy February 23, 2021
    She ROCKS, an organization working for earlier diagnosis and better treatments for ovarian cancer, raised $100,000 through recent virtual luncheon fundraisers to support ongoing research into a potential stem cell-based therapy. Since its inception in 2014, She ROCKS has contributed more than $1 million to support ovarian cancer research underway at the University of North […]
  • Progesterone May Help Drive Spread of Ovarian Cancer, Preclinical Study Shows February 18, 2021
    The hormone progesterone helps to drive the development of metastatic ovarian cancer, and blocking progesterone signaling may be a useful strategy for preventing the cancer, a study in mice suggests. The study, “Targeting progesterone signaling prevents metastatic ovarian cancer,” was published in PNAS. High-grade serous carcinoma (HGSC) is the most common, and most deadly, form of […]
  • InVivo Analytics Granted $1.7M to Advance Preclinical 3D Imaging February 16, 2021
    InVivo Analytics has received $1.7 million to develop and commercialize its next-generation fluorescence imaging device, called InVivoFLUOR, for 3D monitoring of immune cell migration in animal models of cancer, the company announced in a press release. Company researchers plan to validate the system on a mouse model of ovarian cancer. Animals will be treated with […]
  • ENB-003 with Keytruda Shows Promise Against Advanced Solid Tumors February 11, 2021
    ENB Therapeutics’ lead novel anti-cancer therapy, ENB-003, was found to be safe and showed promising anti-tumor activity, when given in combination with Keytruda (pembrolizumab), to adults with different types of advanced solid malignancies, including ovarian cancer and melanoma. These are the early findings of an open-label Phase 1/2 trial (NCT04205227) that has recently finished dosing […]
  • €15M EU Project Seeks to Improve Personalized Medicine Options February 9, 2021
    The European Union is providing nearly €15 million ($18.1 million) over five years to improve personalized medicine options for people with drug-resistant high-grade serous ovarian cancer. The DECIDER project, funded by the EU’s Horizon 2020 research and innovation program, will apply artificial intelligence methods to develop new diagnostic tools to identify — earlier and more […]
  • Early Trial Starts Testing Recommended STRO-002 Dose for Advanced Cancer February 4, 2021
    Sutro Biopharma‘s Phase 1 clinical trial has begun testing the recommended dose of STRO-002 in heavily pretreated patients with advanced ovarian cancer. “We are excited to be part of the STRO-002-GM1 dose-expansion study and to provide additional clinical data to show the potential of this therapeutic for ovarian patients with limited treatment options,” Lainie Martin, MD, […]
  • Blocking Glutamine Metabolism May Help Combat OCCC Tumors February 2, 2021
    Ovarian cancer cells harboring mutations in the ARID1A tumor suppressor gene tend to use the amino acid glutamine as a source of energy more often, making the cells more vulnerable to compounds that interfere with glutamine metabolism, scientists found. As proof, they demonstrated that a compound that inactivates glutaminase (the enzyme that normally breaks down […]
  • BioVaxys Advances Plans to Bring Vaccine to Clinic January 28, 2021
    BioVaxys is planning to request that its investigational vaccine for ovarian cancer, BVX-0918A, be approved for compassionate use in people with advanced ovarian cancer in Europe. The company also plans to file requests to U.S. and European regulatory health authorities requesting authorization to pursue clinical trials of BVX-0918A in the coming months. As part of […]
  • Combining Imaging Methods May Reduce Need for Tumor Biopsies January 26, 2021
    Combining two imaging methods can provide a more accurate sampling of single tumors — like those found in ovarian cancer — thus allowing doctors to capture the diverse cancer cells in the tumor with fewer biopsies, a new study found. The study, “Ultrasound-guided targeted biopsies of CT-based radiomic tumour habitats: technical development and initial experience […]
  • Zejula Now Available in UK as Maintenance Therapy for Advanced Ovarian Cancer January 21, 2021
    The National Institute of Health and Care Excellence (NICE) has recommended the use of Zejula (niraparib) as a maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The medication will be available through the Cancer Drugs Fund (CDF), a funding program that seeks to increase access to promising cancer medicines in […]
  • UV1 Triple Combo Maintenance Therapy Will Be Tested in Phase 2 Trial January 19, 2021
    Ultimovacs will test its experimental cancer vaccine, UV1, as part of a triple-combination therapy for women with relapsed ovarian cancer who have no mutations in their BRCA DNA repair genes. The Phase 2 DOVACC collaboration study will investigate UV1, in combination with AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab) and PARP inhibitor Lynparza (olaparib), as a […]
  • GPS Vaccine-Keytruda Combo Showing Efficacy in Advanced Cancer Patients January 14, 2021
    Combining the experimental vaccine galinpepimut-S (GPS) with the immune checkpoint inhibitor Keytruda (pembrolizumab) induces promising responses in people with metastatic ovarian cancer who failed one or two prior lines of treatment, early data from a Phase 1/2 trial show. The combination kept all eight patients in a first evaluated group in the trial (NCT03761914) without signs […]
  • Lynparza Approved in Japan to Treat Certain Advanced Ovarian Cancers January 12, 2021
    Lynparza (olaparib) has been approved in Japan as a maintenance treatment for women with advanced ovarian cancer who responded to a first-line chemotherapy regimen containing bevacizumab, AstraZeneca and Merck announced in a press release. The approval, for patients whose cancer is positive for homologous recombination deficiency (HRD), is based on data from the PAOLA-1 Phase 3 trial (NCT02477644), […]
  • $34M Funding Helps Speed Up New Class of Cancer Diagnostics January 7, 2021
    InterVenn Biosciences has raised $34 million to commercialize a new diagnostic tool for ovarian cancer, based on the identification of circulating proteins containing sugar molecules (glycoproteins). The company expects to validate the diagnostic tool intended for immediate clinical use and drive rapidly expanding partnership projects. The funding will also help accelerate the use of glycoproteins in […]